RF Positive Plasma Titer >700
RF Positive Plasma Titer >700

Human Plasma, Rheumatoid Factor (RF) Positive, Titer >700

from $125.00

Our Human Plasma, Rheumatoid Factor (RF) Positive (Cat# 04.1003), with high titers exceeding 700 IU/mL, is expertly sourced from donors exhibiting pronounced RF elevation, reflecting advanced autoimmune conditions such as rheumatoid arthritis. This disease-state plasma is engineered for high-precision research, next‑generation immunoassay development, stringent quality control, and specialized diagnostic workflows.

Manufactured under rigorous regulatory protocols, each lot delivers consistent purity, integrity, and full traceability. Comprehensive screening confirms RF positivity above 700 IU/mL, providing a reliable standard for high-sensitivity assay calibration and critical diagnostic quality control.

Key Features:

  • Ultra-High RF Titer: Validated RF-positive plasma with titers >700 IU/mL.

  • Regulatory Assurance: Processed under strict quality systems to maintain reproducibility and safety.

  • Extensive Safety Testing: Confirmed non-reactive for HIV 1/2, HIV-1 (NAT), HBsAg, HBV (NAT), HCV, HCV (NAT), and Syphilis via FDA-approved methods.

  • Versatile Formats: Available in customizable aliquot sizes to suit diverse research and manufacturing needs.

Ideal Applications:

  • Development of high-sensitivity immunoassays for autoimmune biomarkers

  • Advanced quality control in diagnostic assay production

  • Research on inflammatory pathways and autoantibody dynamics

Note: Users must validate product suitability, establish expiration dates, and qualify performance for specific applications.

Volume:

Our Human Plasma, Rheumatoid Factor (RF) Positive (Cat# 04.1003), with high titers exceeding 700 IU/mL, is expertly sourced from donors exhibiting pronounced RF elevation, reflecting advanced autoimmune conditions such as rheumatoid arthritis. This disease-state plasma is engineered for high-precision research, next‑generation immunoassay development, stringent quality control, and specialized diagnostic workflows.

Manufactured under rigorous regulatory protocols, each lot delivers consistent purity, integrity, and full traceability. Comprehensive screening confirms RF positivity above 700 IU/mL, providing a reliable standard for high-sensitivity assay calibration and critical diagnostic quality control.

Key Features:

  • Ultra-High RF Titer: Validated RF-positive plasma with titers >700 IU/mL.

  • Regulatory Assurance: Processed under strict quality systems to maintain reproducibility and safety.

  • Extensive Safety Testing: Confirmed non-reactive for HIV 1/2, HIV-1 (NAT), HBsAg, HBV (NAT), HCV, HCV (NAT), and Syphilis via FDA-approved methods.

  • Versatile Formats: Available in customizable aliquot sizes to suit diverse research and manufacturing needs.

Ideal Applications:

  • Development of high-sensitivity immunoassays for autoimmune biomarkers

  • Advanced quality control in diagnostic assay production

  • Research on inflammatory pathways and autoantibody dynamics

Note: Users must validate product suitability, establish expiration dates, and qualify performance for specific applications.

 
Human Plasma, Rheumatoid Factor (RF) Positive, Titer >700
Download Spec Sheet

Intended Use and Customer Responsibility

Golden West BioSolutions, LLC products are specifically designed for research and the manufacturing of non-injectable products. It is the customer's responsibility to handle these products safely and responsibly. Golden West BioSolutions, LLC is not liable for any injuries stemming from the use or handling of its products. All disposal procedures must align with federal and state regulations.

Quality Assurance Disclaimer

Golden West BioSolutions, LLC does not warrant the performance of their products in specific applications. Customers are responsible for determining the suitability and qualification of Golden West BioSolution products for their intended use. Given the natural variation in biological materials, Golden West BioSolutions, LLC also recommends consideration of lot-to-lot evaluation.